Outlook Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Bob Jahr

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	8.61%
CEO görev süresi	1yr
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	7.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bob Jahr'un ücretlendirmesi Outlook Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	-US$61m
Dec 31 2025	n/a	n/a	-US$103m
Sep 30 2025	US$2m	US$150k	-US$62m

Tazminat ve Piyasa: Bob 'nin toplam tazminatı ($USD 1.74M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 853.62K ).

Tazminat ve Kazançlar: Bob şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Bob Jahr (53 yo)

1yr

Görev süresi

US$1,741,757

Tazminat

Mr. Robert Charles Jahr, also known as Bob, is President, Chief Executive Officer & Director of Outlook Therapeutics, Inc. from July 1, 2025. From September 2018 to April 2020, he served as Vice President...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Jahr	President	1yr	US$1.74m	Veri yok
Lawrence Kenyon	EVP, CFO	10.8yrs	US$476.17k	0.0032% € 5.4k
Joel Prieve	Senior Vice President of Licensing and M&A	4.4yrs	Veri yok	Veri yok
Surendra Sharma	Senior Vice President of Medical Affairs	3.5yrs	Veri yok	Veri yok
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	Veri yok	Veri yok
Jedd Comiskey	Senior VP - Head of Europe	2.7yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 41O 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Jahr	President	1yr	US$1.74m	Veri yok
Lawrence Kenyon	EVP, CFO	7.9yrs	US$476.17k	0.0032% € 5.4k
Kurt Hilzinger	Independent Director	10.6yrs	US$842.00k	0.23% € 382.0k
Ralph Thurman	Lead Independent Director	8.3yrs	US$836.50k	0.0030% € 5.0k
Julian Gangolli	Independent Non-Employee Director	6.3yrs	US$690.50k	0% € 0
Gerd Auffarth	Independent Non-Employee Director	6.3yrs	US$458.00k	0% € 0
Faisal Sukhtian	Independent Chairman of the Board	8.8yrs	US$1.00m	0.12% € 199.2k
Yezan Haddadin	Independent Director	8.8yrs	US$974.00k	0.035% € 59.6k
Andong Huang	Independent Director	6.1yrs	US$425.00k	0% € 0

7.9yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 41O 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/07/31 11:00
Gün Sonu Hisse Fiyatı	2026/07/31 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/09/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Outlook Therapeutics, Inc. 9 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Edward Woo	Ascendiant Capital Markets LLC
Brian Kemp Dolliver	Brookline Capital Markets
Kumaraguru Raja	Brookline Capital Markets

Outlook Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Director recently bought €152k worth of stock

Insufficient new directors

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Insufficient new directors

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Recent updates

Forecast to breakeven in 2028

Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet Amd

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. Regains Compliance with Minimum Bid Price Requirement

Outlook Therapeutics, Inc. Announces FDA Acceptance Of Resubmitted Biologics License Application For ONS-5010/LYTENAVA (Bevacizumab-Vikg) As A Treatment For Wet AMD

Independent Director recently bought €152k worth of stock

Outlook Therapeutics, Inc. Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process For ONS-5010/LYTENAVA (Bevacizumab-Vikg) And Plans To Resubmit BLA To FDA In June 2026

Insufficient new directors

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Inc Completes Federal Dispute Resolution Meeting with Fda for Ons-5010/Lytenavatm

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Inc. Announces FDA Accepts Formal Dispute Resolution Request for ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. announced that it has received $18.36 million in funding from Atlas Sciences, LLC

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics Provides Update Following Type A Meeting With FDA Regarding ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Outlook Therapeutics, Inc. Receives Notice of Potential Delisting Due to Low Stock Price on Nasdaq

Outlook Therapeutics, Inc. Submits Type A Meeting Request to FDA Following Complete Response Letter

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd

Insufficient new directors

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics, Inc. Announces Type A Meeting with the U.S. Food and Drug Administration Resubmission for Ons-5010

Outlook Therapeutics, Inc. Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™? (Bevacizumab-Vikg) for the Treatment of Wet Amd

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc.(NasdaqCM:OTLK) dropped from Russell 2000 Index

Outlook Therapeutics®? Announces Smc Recommendation of Lytenava™ (Bevacizumab Grapa) for the Treatment of Wet Amd

Outlook Therapeutics, Inc. Announces Commercial Launch of LYTENAVA (bevacizumab G gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $13 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. Announces U.S. Food and Drug Administration Resubmission of ONS-5010 Biologics License Application

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc., Annual General Meeting, Mar 11, 2025

Outlook Therapeutics, Inc. Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from Norse Eight Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial

Outlook Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Outlook Therapeutics, Inc. Streamlines Operations

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc Announces Resignation of Russell Trenary as President

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Forecast to breakeven in 2027

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

New major risk - Financial position

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Insufficient new directors

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

New major risk - Shareholder dilution

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics, Inc. Provides Update on Type A Meetings with FDA